A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA) Clinical Trial

Official title:
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)

Status Completed

Clinical Trial Summary

A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Arthritis
Arthritis, Juvenile
Juvenile Idiopathic Arthritis (JIA)

Clinical Trial Details

NCT number	NCT01544114
Study type	Interventional
Source	Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact
Status	Completed
Phase	Phase 4
Start date	April 2012
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05534347` - Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Recruiting	`NCT05710640` - Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA	Phase 2
Active, not recruiting	`NCT03725007` - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis	Phase 1
Recruiting	`NCT03245801` - CAPRI National Juvenile Idiopathic Arthritis Registry
Completed	`NCT05000216` - COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Phase 2